Given that prior studies have demonstrated that SMARCB1 loss leads to profound replication and proteotoxic stress,8, 10, 11 and that neddylation inhibition can further promote these toxicities within cells, we hypothesised that the addition of pevonedistat to cytotoxic chemotherapy such as carboplatin could synergistically lead to RMC cell death and tumour growth inhibition. Here, SMARCB1 is linked to neoplasm.